Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Systemic therapy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    3,666 result(s) found for: Systemic therapy. Displaying page 1 of 184.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2007-006035-32 Sponsor Protocol Number: 2300/2007 Start Date*: 2007-11-15
    Sponsor Name:AZIENDA OSPEDALIERA PISANA
    Full Title: Assessment of endothelial function and vasal response in patients with Systemic Sclerosis and Hypercholesterolemia, before and after simvastatin treatment.
    Medical condition: Systemic Sclerosis and Hypercholesterolemia.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10042953 Systemic sclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-019977-14 Sponsor Protocol Number: CILOS-RAY2010 Start Date*: 2010-11-04
    Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA SAN MARTINO GENOVA
    Full Title: Efficacy of Cilostazol for the treatment of Raynaud’s Phenomenon in patients affected by Systemic Sclerosis
    Medical condition: Patients affected by Systemic Sclerosis with Raynaud’s Phenomenon
    Disease: Version SOC Term Classification Code Term Level
    9.1 10042953 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-000230-33 Sponsor Protocol Number: HYDROXYSSc Start Date*: 2022-01-26
    Sponsor Name:UMBERTO I - POLICLINICO DI ROMA
    Full Title: A DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED, ADD-ON TRIAL EVALUATING EFFICACY AND SAFETY OF HYDROXYCHLOROQUINE IN EARLY SYSTEMIC SCLEROSIS (SSc)- HYDROXYSSc
    Medical condition: Systemic Sclerosis (SSc) is a rare and orphan disease (DPCM 12 gennaio 2017-GU SG n°65-S.O. n°15 - 18/03/2017), characterized by immunological, vascular and fibrotic abnormalities. The estimated in...
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10042953 Systemic sclerosis LLT
    21.0 100000004859 10042953 Systemic sclerosis LLT
    21.0 100000004859 10042953 Systemic sclerosis LLT
    21.0 100000004859 10042953 Systemic sclerosis LLT
    21.0 100000004859 10042953 Systemic sclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-005322-68 Sponsor Protocol Number: farm 69j aj9 Start Date*: 2007-10-30
    Sponsor Name:AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI
    Full Title: Low-dose oral imatinib in the treatment of scleroderma pulmonary involvement: a phase II pilot study
    Medical condition: Systemic Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    6.1 10042953 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-013468-37 Sponsor Protocol Number: Protocol code BA7 Start Date*: 2010-09-29
    Sponsor Name:Royal National Hospital for Rheumatic Disease
    Full Title: A short-term open-label single site pilot study evaluating the use of asasantin retard therapy in the management of Raynaud’s phenomenon.
    Medical condition: Primary Raynaud's Phenomenon and Systemic Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10042953 Systemic Sclerosis LLT
    12.0 10037917 Raynaud's phenomenon LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000797-35 Sponsor Protocol Number: EC11-287 Start Date*: 2013-05-24
    Sponsor Name:Hospital Virgen de la Salud, Toledo (Spain).
    Full Title: Clinical Trial with Cladribine (2-CDA) and Pegylated Interpheron Alfa-2a in patients with advanced systemic mastocytosis carrying D816V KIT mutation (or different mutations involving exon 17 of KIT).
    Medical condition: Advanced systemic mastocytosis carrying the D816V KIT mutation (or different exon 17 KIT mutations).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-001391-12 Sponsor Protocol Number: TV-4710/201 Start Date*: 2005-07-27
    Sponsor Name:TEVA Pharmaceutical Industries, Ltd.
    Full Title: A multi-national, multi-centre, randomized, double-blind, placebo-controlled, multiple-dose, parallel-group study to assess the efficacy, tolerability and safety of three doses of edratide (TV-4710...
    Medical condition: Systemic lupus erythematosus (SLE)
    Disease: Version SOC Term Classification Code Term Level
    7.1 10042945 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) GB (Completed) ES (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-004404-35 Sponsor Protocol Number: I4V-MC-JAHH Start Date*: 2016-04-06
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of Baricitinib in Patients with Systemic Lupus Erythematosus (SLE)
    Medical condition: Patients with Systemic Lupus Erythematosus (SLE)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004859 10025139 Lupus erythematosus systemic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) PL (Completed) ES (Completed) FR (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2012-004955-35 Sponsor Protocol Number: 1883/12 Start Date*: 2013-07-29
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: A single-center randomized double-blind placebo-controlled trial “Treatment of Systemic Sclerosis with Rituximab: evaluation of the effectiveness of B-cell depletion therapy”
    Medical condition: SYSTEMIC SCLEROSIS
    Disease: Version SOC Term Classification Code Term Level
    16.0 10028395 - Musculoskeletal and connective tissue disorders 10042953 Systemic sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002586-39 Sponsor Protocol Number: MC-TER.2/SSc Start Date*: 2016-08-03
    Sponsor Name:medac GmbH
    Full Title: Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Terguride Plus Symptomatic Therapy in Subjects With Diffuse Cutaneous Systemic Sclerosis
    Medical condition: Diffuse cutaneous systemic sclerosis (dcSSc)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10028395 - Musculoskeletal and connective tissue disorders 10042953 Systemic sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) PT (Prematurely Ended) HU (Prematurely Ended) BE (Prematurely Ended) GB (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-006214-16 Sponsor Protocol Number: cro967 Start Date*: 2010-02-23
    Sponsor Name:Imperial College
    Full Title: A randomised placebo controlled trial of rosuvastatin in systemic lupus erythematosus.
    Medical condition: Systemic lupus erythematosus.
    Disease: Version SOC Term Classification Code Term Level
    13.1 10028395 - Musculoskeletal and connective tissue disorders 10042944 Systemic lupus erythematosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-005392-16 Sponsor Protocol Number: ORDI-03 Start Date*: 2012-05-23
    Sponsor Name:Dr Josep Ordi Ros
    Full Title: Study to evaluate the efficacy and safety of Anakinra in the treatment of articular manifestations refractory to conventional therapy in Systemic Lupus Erythematosus patients
    Medical condition: Systemic lupus erythematosus
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-004008-36 Sponsor Protocol Number: ANAK-01 Start Date*: 2005-10-27
    Sponsor Name:ISTITUTO GIANNINA GASLINI
    Full Title: Efficacy and safety of treatment with Anakinra in patients with CINCA/MUCKLE-WELLS syndrome and systemic juvenile idiopathic arthritis
    Medical condition: CINCA/MUCKLE-WELLS syndrome and systemic juvenile idiopathic arthritis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10010331 Congenital, familial and genetic disorders SOC
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-002184-14 Sponsor Protocol Number: IM128-027 Start Date*: 2014-12-26
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of BMS-931699 vs. Placebo on a Background of Limited Standard of care in the Treatmen...
    Medical condition: Active Systemic Lupus Erythematosus
    Disease: Version SOC Term Classification Code Term Level
    17.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Prematurely Ended) HU (Completed) IT (Prematurely Ended) NL (Completed)
    Trial results: View results
    EudraCT Number: 2018-001808-11 Sponsor Protocol Number: ID-064A202 Start Date*: 2019-01-14
    Sponsor Name:Idorsia Pharmaceuticals Ltd
    Full Title: A Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of cenerimod in subjects with moderate to severe syste...
    Medical condition: Moderate to severe systemic lupus erythematosus
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (GB - no longer in EU/EEA) DE (Completed) ES (Ongoing) HU (Completed) BG (Completed) PL (Completed) GR (Completed) IT (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2020-005776-35 Sponsor Protocol Number: 230LE304 Start Date*: 2021-12-24
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of BIIB059 in Adult Participants With Active Systemic Lupus Erythematosus Receiving Ba...
    Medical condition: systemic lupus erythematosus
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10025139 Lupus erythematosus systemic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) DE (Trial now transitioned) HU (Trial now transitioned) CZ (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2025-000142-26 Sponsor Protocol Number: 217091 Start Date*: 2025-04-29
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A Multi-Centre, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Subcutaneously Administered Belimumab Plus Standard Therapy in Chinese Paediatric Participants with Systemic Lupus Er...
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2020-004047-86 Sponsor Protocol Number: AIS-A03 Start Date*: Information not available in EudraCT
    Sponsor Name:Alpine Immune Sciences, Inc.
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ALPN-101 IN SYSTEMIC LUPUS ERYTHEMATOSUS
    Medical condition: Systemic lupus erythematosus (SLE)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10040785 - Skin and subcutaneous tissue disorders 10042946 Systemic lupus erythematosus rash PT
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042948 Systemic lupus erythematosus syndrome aggravated LLT
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042947 Systemic lupus erythematosus synd LLT
    20.0 100000004857 10029142 Nephritis systemic lupus erythematosus LLT
    20.1 10022891 - Investigations 10067657 Systemic lupus erythematosus disease activity index increased PT
    20.0 10022891 - Investigations 10067658 Systemic lupus erythematosus disease activity index decreased PT
    20.1 10022891 - Investigations 10067659 Systemic lupus erythematosus disease activity index abnormal PT
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10080670 Systemic lupus erythematosus reactivation LLT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10073694 Lupus pleurisy PT
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10040968 SLE arthritis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) PL (Completed) ES (Prematurely Ended) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-020859-30 Sponsor Protocol Number: SL0012 Start Date*: 2011-05-25
    Sponsor Name:UCB Inc.
    Full Title: A phase 3, multicenter, open-label, extension study to asssess the safety and tolerability of Epratuzumab treatment in systemic lupus erythematosus subjects (EMBODY 4)
    Medical condition: Systemic Lupus Erythematosus
    Disease: Version SOC Term Classification Code Term Level
    18.0 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Prematurely Ended) DE (Completed) CZ (Prematurely Ended) GB (Prematurely Ended) HU (Completed) BG (Prematurely Ended) LT (Prematurely Ended) IT (Completed) EE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-006544-26 Sponsor Protocol Number: INTONATE Start Date*: 2022-12-23
    Sponsor Name:A.S.L. TO 2
    Full Title: INTONATE INtensified procol for lupus nephritis with riTuximab and nO maintaiNAnce ThErapy
    Medical condition: lupus nephritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004857 10029142 Nephritis systemic lupus erythematosus LLT
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 13 12:53:34 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA